HEALIOS K.K. (4593) Stock Price

Helios is a company dedicated to treating intractable diseases using stem cell technology. The company primarily conducts research, development, and manufacturing of somatic stem cell regenerative medicines and iPS cell-related regenerative medicine products. Operating as a single pharmaceutical business segment, Helios aims to provide innovative treatment methods by leveraging stem cell technology.

In the somatic stem cell regenerative medicine field, the company develops new treatment approaches using neural stem cells and mesenchymal stem cells. Helios is particularly focused on developing treatments for acute cerebral infarction and acute respiratory distress syndrome (ARDS) using Athersys's somatic stem cell product MultiStem®. ARDS can occur as a complication in severe pneumonia and COVID-19 patients, creating a need for new therapeutic approaches to improve patient outcomes.

In the iPSC regenerative medicine field, Helios develops products using iPS cells to create cells with functions similar to those in the human body, aiming to restore function. iPS cells have the ability to differentiate into various tissue and organ cells, expanding the possibilities of regenerative medicine. Helios is advancing the development of next-generation iPS cells called "Universal Donor Cells (UDC)" that reduce the risk of immune rejection.

Additionally, Helios is developing iPSC regenerative medicines in cancer immunotherapy, ophthalmology, and liver disease treatment. In cancer immunotherapy, the company is researching treatment methods using natural killer cells enhanced through gene editing technology. In ophthalmology, Helios is developing treatments for age-related macular degeneration using iPS cell-derived retinal pigment epithelial cells.

Helios is a company dedicated to treating intractable diseases using stem cell technology, with a particular focus on developing regenerative medicines utilizing iPS cells. The company has established an integrated structure that handles everything from research and development to manufacturing and commercialization, guided by its vision of delivering cure and hope to patients worldwide.

The company's growth strategy consists of two perspectives: short-term and long-term. In the short term, it aims to strengthen its development pipeline targeting regulatory approval in Japan and establish a revenue base. Specifically, the company is pursuing approval of HLCM051 in the somatic stem cell regenerative medicine field and advancing clinical trials targeting acute cerebral infarction and ARDS.

Long-term, the company is focusing on establishing innovative foundational technologies to realize the practical application of iPSC regenerative medicines. In particular, it is advancing research into next-generation iPS cell production using gene-editing technology and cancer immunotherapy. Through these efforts, the company aims to establish a de facto standard position globally.

Additionally, Helios has established Saisei Ventures LLC in the United States to strengthen technology acquisition and collaboration with other ventures through investments in the biotech sector. This aims to secure technologies that contribute to the company's pipeline.

Through a multi-layered development strategy in disease areas with high unmet medical needs, the company seeks to reduce risk and enhance corporate value. This enables the company to achieve sustainable growth and provide new treatment options to patients worldwide.